Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of
psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in
vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary
objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating
disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals,
and body weight.